- Home
- HFRO vs QURE Comparison
HFRO vs QURE Comparison
Compare HFRO & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFRO
- QURE
- Stock Information
- Founded
- HFRO 2000
- QURE 1998
- Country
- HFRO United States
- QURE Netherlands
- Employees
- HFRO N/A
- QURE N/A
- Industry
- HFRO Finance/Investors Services
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- HFRO Finance
- QURE Health Care
- Exchange
- HFRO Nasdaq
- QURE Nasdaq
- Market Cap
- HFRO 402.7M
- QURE 432.6M
- IPO Year
- HFRO N/A
- QURE 2007
- Fundamental
- Price
- HFRO $5.87
- QURE $6.28
- Analyst Decision
- HFRO
- QURE Buy
- Analyst Count
- HFRO 0
- QURE 6
- Target Price
- HFRO N/A
- QURE $19.50
- AVG Volume (30 Days)
- HFRO 421.7K
- QURE 823.3K
- Earning Date
- HFRO 01-01-0001
- QURE 11-05-2024
- Dividend Yield
- HFRO 12.00%
- QURE N/A
- EPS Growth
- HFRO N/A
- QURE N/A
- EPS
- HFRO 1.23
- QURE N/A
- Revenue
- HFRO $44,535,929.00
- QURE $27,707,000.00
- Revenue This Year
- HFRO N/A
- QURE $187.60
- Revenue Next Year
- HFRO N/A
- QURE $51.90
- P/E Ratio
- HFRO $5.50
- QURE N/A
- Revenue Growth
- HFRO N/A
- QURE N/A
- 52 Week Low
- HFRO $5.92
- QURE $3.73
- 52 Week High
- HFRO $9.38
- QURE $11.35
- Technical
- Relative Strength Index (RSI)
- HFRO 35.00
- QURE 59.75
- Support Level
- HFRO $5.82
- QURE $5.23
- Resistance Level
- HFRO $6.24
- QURE $6.55
- Average True Range (ATR)
- HFRO 0.13
- QURE 0.49
- MACD
- HFRO -0.04
- QURE 0.17
- Stochastic Oscillator
- HFRO 10.42
- QURE 87.14
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. The company's portfolio of investments includes different industry investments such as Financial, Communication Services, Energy, Healthcare, Materials, and others.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.